droplet-based PCR
Bio-Rad plans to drive adoption of Stilla's all-in-one Nio+ dPCR system while also incorporating its own assays to expand the menu.
The firm expects growth in its ddPCR business this year as it launches new products and the biopharma segment begins to recover from a funding slump.
Bio-Rad Q2 Revenues Fall 2 Percent
The sales decline was largely due to a slowdown in productivity related to the recent launch of the company's global enterprise resource planning system in Western Europe.